Pediatrix (MD) director receives 7,196 restricted shares in annual equity award

Rhea-AI Filing Summary

Starcher John M. Jr. reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director John M. Starcher Jr. received an equity grant of 7,196 shares of common stock as a compensation award. The shares were granted at no cash cost to him and increase his direct holdings to 73,260 shares.

These are restricted shares granted under the company’s Amended and Restated 2008 Incentive Compensation Plan in connection with an annual equity award. The restricted stock is scheduled to fully vest on May 7, 2027, meaning the shares become unrestricted for him on that date if vesting conditions are satisfied.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Starcher John M. Jr.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,196	$0.00	--

Holdings After Transaction: Common Stock — 73,260 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted shares granted: 7,196 shares Grant price per share: $0.0000 per share Total shares after grant: 73,260 shares +1 more

4 metrics

Restricted shares granted 7,196 shares Annual equity award of common stock

Grant price per share $0.0000 per share Stated transaction price for restricted stock grant

Total shares after grant 73,260 shares Direct holdings following the transaction

Vesting date May 7, 2027 Date restricted shares are scheduled to vest

Key Terms

Restricted shares, Amended and Restated 2008 Incentive Compensation Plan, annual equity award, vest, +1 more

5 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Amended and Restated 2008 Incentive Compensation Plan financial

"granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

annual equity award financial

"Incentive Compensation Plan, in connection with annual equity award."

vest financial

"Shares will vest on May 7, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starcher John M. Jr.

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		7,196	A	$0	73,260	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.

Remarks:

See Exhibit 24.1 - Power of Attorney

	Mary Ann E. Moore, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pediatrix Medical Group (MD) report for John M. Starcher Jr.?

Pediatrix Medical Group reported that director John M. Starcher Jr. received 7,196 restricted shares of common stock as an annual equity award. The grant was made at no cash cost and is structured as a compensation-related stock award.

How many Pediatrix Medical Group (MD) shares does John M. Starcher Jr. hold after this Form 4?

After the award, John M. Starcher Jr. directly holds 73,260 shares of Pediatrix Medical Group common stock. This total reflects the addition of 7,196 restricted shares granted as part of his annual equity compensation package.

When do the restricted shares granted to John M. Starcher Jr. at Pediatrix (MD) vest?

The 7,196 restricted shares granted to John M. Starcher Jr. are scheduled to vest on May 7, 2027. Vesting on that date means the restrictions lapse and the shares become fully owned, subject to any remaining plan conditions.

What plan governs the restricted stock award reported in this Pediatrix Medical Group (MD) Form 4?

The restricted stock award was granted under Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan. This plan governs equity-based compensation, including annual equity awards, for eligible directors, executives, and other participants.

Was the Pediatrix (MD) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 shows a compensation grant, not an open-market purchase. John M. Starcher Jr. acquired 7,196 restricted shares at a stated price of $0.0000 per share as an annual equity award under the company’s incentive compensation plan.